Diagnostic biomarker for early stage of Alzheimer's disease: Current state and view in the future

Psychogeriatrics

Volumn 10, Issue 2, 2010, Pages 49-52

  Urakami, Katsuya ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; WHEAT GERM AGGLUTININ;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; DISEASE SEVERITY; EDITORIAL; FUTUROLOGY; HUMAN; MEASUREMENT; PRIORITY JOURNAL; PROTEOMICS; SCREENING TEST;

ALZHEIMER DISEASE; AMYLOIDOGENIC PROTEINS; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FORECASTING; HUMANS; TAU PROTEINS;

EID: 77955940000     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/j.1479-8301.2010.00331.x     Document Type: Editorial

References (11)

1. Urakami K, Adachi Y, Wakutani Y. Epidemiologic and genetic studies of dementia of the Alzheimer type in Japan. Dement Geriatr Cogn Disord 1998, 9:294-298.
2. Wakutani Y, Kusumi M, Wada K. Longitudinal changes in the prevalence of dementia in a Japanese rural area. Psychogeriatrics 2007, 7:150-154.
3. Kanai M, Matsubara E, Isoe K. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40 and Aβ1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998, 44:17-26.
4. Takeda M, Tanaka T, Arai H. Basic and clinical studies on the measurement of beta-amyloid (1-42) in cerebrospinal fluid as a diagnostic marker for Alzheimer's disease and related disorders: multicenter study in Japan. Psychogeriatrics 2001, 1:56-63.
5. Itoh N, Arai H, Urakami K. Large-Scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 2001, l50:150-156.
6. Urakami K, Mori M, Wada K. A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neurosci Lett 1998, 259:1-3.
7. Urakami K, Wada K, Arai H. Diagnostic significance of tau proteins in cerebrospinal fluids from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci 2001, 183:95-98.
8. Inoue M, Jinbo D, Nakamura Y, Taniguchi M, Urakami K. Development and evaluation of a computerized test battery for Alzheimer's Disease screening in community-based setting. Am J Alzheimer's Dis Other Demen 2009, 15:249-315.
9. German DC, Gurnani P, Nandi A. Serum biomarkers for Alzheimer's disease: proteomic discovery. Biomed Pharmacother 2007, 61:383-389.
10. Wada-Isoe K, Kitayama M, Imamura K. Serum proteomic profiling of dementia with Lewy bodies: diagnostic potential of SELDI-TOF MS analysis. J Neural Transm 2007, 114:1579-1583.
11. Taniguchi M, Okayama Y, Urakami K. Suger chains cerebrospinal fluid transferrin as a new biological marker of Alzheimer's disease. Dement Geriatr Cogn Disord 2008, 26:117-122.